Absence of Rgs5 prolongs cardiac repolarization and predisposes to ventricular tachyarrhythmia in mice

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 6, 2012, Pages 880-890

  Qin, Mu ^a,b   Huang, He ^a,b   Wang, Teng ^b   Hu, He ^a,b   Liu, Yu ^a,b   Cao, Hong ^b   Li, Hongliang ^b   Huang, Congxin ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Arrhythmia; K+ currents; Repolarization; Rgs5

Indexed keywords

POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KV2.1; POTASSIUM CHANNEL KV4.2; POTASSIUM CHANNEL KV4.3; REGULATOR OF G PROTEIN SIGNALING 5; RGS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL;

ACTION POTENTIALS; ANGIOTENSIN II; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HEART; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; POTASSIUM; POTASSIUM CHANNELS; RECEPTOR, ANGIOTENSIN, TYPE 1; RGS PROTEINS; TACHYCARDIA, VENTRICULAR;

MUS;

EID: 84869094995     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.10.003     Document Type: Article

References (33)

1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992, 327:227-233.
2. Manzur M., Ganss R. Regulator of G protein signaling 5: a new player in vascular remodeling. Trends Cardiovasc Med 2009, 19:26-30.
3. Xiao B., Zhang Y., Niu W.Q., Gao P.J., Zhu D.L. Haplotype-based association of regulator of G-protein signaling 5 gene polymorphisms with essential hypertension and metabolic parameters. Clin Chem Lab Med 2009, 47:1483-1488.
4. Wang Y.H., Shi C.X., Dong F., Sheng J.W., Xu Y.F. Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor. Br J Pharmacol 2008, 154:429-439.
5. Magdalini T., Diane G., Till H., Mareike K.B., Helga V., Kamila S., et al. Molecular and functional remodeling of Ito by angiotensin II in the mouse left ventricle. J Moll Cell Cardiol 2010, 48:140-151.
6. Andrea A.D., Christophe B., Daniel C., Hugues A., Thierry P. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation. J Moll Cell Cardiol 2007, 42:63-70.
7. Li H.L., He C.W., Feng J.H., Zhang Y., Tang Q.Z., Bian Z.Y., et al. Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 2010, 107:13818-13823.
8. Zhang Z., He Y.X., Dipika T., Xu D.Y., Valeriy T., Zhang Q., et al. Functional roles of Cav1.3(1D) calcium channels in atria insights gained from gene-targeted null mutant mice. Circulation 2005, 112:1936-1944.
9. Kate S.S., Glyn T., Catharine A.G., William H.C., Andrew A.G., Huang L.H. Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/△ murine hearts modeling long QT syndrome 3. J Physiol 2007, 58:69-84.
10. Casimiro M.C., Knollmann B.C., Ebert S.N., Vary J.C., Greene A.E., Franz M.R., et al. Targeted disruption of the Kcnq1 gene produces a mouse model of Jervell and Lange-Nielsen Syndrome. Proc Natl Acad Sci U S A 2001, 98:2526-2531.
11. Reil J.C., Hohl M., Oberhofer M., Kazakov A., Kaestner L., Mueller P., et al. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodeling. Cardiovasc Res 2010, 87:485-493.
12. Brunet S., Aimond F., Li H., Guo W., Eldstrom J., Fedida D., et al. Heterogeneous expression of repolarizing, voltage-gated K+ currents in adult mouse ventricles. J Physiol 2004, 559:103-120.
13. Gu S., Cifelli C., Wang S., Heximer S.P. RGS proteins: identifying new GAPs in the understanding of blood pressure regulation and cardiovascular function. Clin Sci (Lond) 2009, 116:391-399.
14. Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000, 52:415-472.
15. Zhang C., Yasuno S., Kuwahara K., Zankov D.P., Kobori A., Makiyama T. Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy. Circ J 2006, 70:335-341.
16. Domenighetti A.A., Boixel C., Cefai D., Abriel H., Pedrazzini T. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation. J Mol Cell Cardiol 2007, 42:63-70.
17. Katy R., Pierre P., Mona N., Celine F. Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization. Cardiovasc Res 2008, 78:53-62.
18. Hayabuchi Y., Davies N.W., Standen N.B. Angiotensin II inhibits rat arterial KATP channels by inhibiting steady-state protein kinase A activity and activating protein kinase C1. J Physiol 2001, 530:193-205.
19. Zhang T.T., Takimoto K., Stewart A.F.R., Zhu C., Levitan E.S. Independent regulation of cardiac Kv4.3 potassium channel expression by angiotensin II and phenylephrine. Circ Res 2001, 88:476-482.
20. Shimoni Y. Inhibition of the formation or action of angiotensin II reverses attenuated Kt currents in type 1 and type 2 diabetes. J Physiol 2001, 537:83-92.
21. London B., Guo W., Pan X., Lee J.S., Shusterman V., Rocco C.J., et al. Targeted replacement of KV1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of I(K, slow) and resistance to drug-induced qt prolongation. Circ Res 2001, 88:940-946.
22. Zhou J., Kodirov S., Murata M., Buckett P.D., Nerbonne J.M., Koren G. Regional upregulation of Kv2.1-encoded current, IK, slow2, in Kv1DN mice is abolished by crossbreeding with Kv2DN mice. Am J Physiol Heart Circ Physiol 2003, 284:H491-H500.
23. El-Sherif N. Mechanism of ventricular arrhythmias in the long QT syndrome: on hermeneutics. J Cardiovasc Electrophysiol 2001, 12:973-976.
24. Restivo M., Caref E.B., Kozhevnikov D.O., El-Sherif N. Spatial dispersion of repolarization is a key factor in the arrhythmogenicity of long QT syndrome. J Cardiovasc Electrophysiol 2004, 15:323-331.
25. Thomas G., Killeen M.J., Gurung I.S., Hakim P., Balasubramaniam R., Goddard C.A., et al. Mechanisms of ventricular arrhythmogenesis in mice following targeted disruption of KCNE1 modelling long QT syndrome 5. J Physiol 2007, 578:99-114.
26. McMullen J.R., Jennings G.L. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007, 34:255-262.
27. Nattel S., Maguy A., Le Bouter S., Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007, 87:425-456.
28. Salama G., Baker L., Wolk R., Barhanin J., London B. Arrhythmia phenotype in mouse models of human long QT. J Interv Card Electrophysiol 2009, 24:77-87.
29. Guo W., Li H., London B., Nerbonne J.M. Functional consequences of elimination of i(to, f) and i(to, s): early afterdepolarizations, atrioventricular block, and ventricular arrhythmias in mice lacking Kv1.4 and expressing a dominant-negative Kv4 alpha subunit. Circ Res 2000, 87:73-79.
30. + channel diversity in the mammalian myocardium. J Physiol 2000, 525:285-298.
31. Ks channel expression in adult murine heart. Am J Physiol Heart Circ Physiol 2003, 284:H168-H175.
32. Kuck K.H. Ventricular tachycardia in patients with an implantable defibrillator warrants catheter ablation. Circ Arrhythm Electrophysiol 2009, 2:713-720.
33. Patel C., Yan G.X., Kocovic D., Kowey P.R. Ventricular tachycardia ablation versus drugs for preventing ICD shocks. Circ Arrhythm Electrophysiol 2009, 2:705-712.